Figure 3

Cytotoxicity against colorectal cancer cell line mediated by cetuximab. A-B: PBMCs from healthy volunteers (n = 5, mean age 31 years) and from 5 mCRC patients (n = 5) mean age 52 years) were tested for cytotoxicity against DLD1, using four E:T ratio in the absence (PBMCs activity) or presence of cetuximab (10 μ g/ml). Points mean of a triplicate experiment; bars: SD. C-D: PBMCs from 5 healthy donors and 5 mCRC were tested for the cytotoxicity in the presence or the absence of cetuximab, for the effect of IL-2 stimulation and CD56⁺ cells depletion. Columns, mean; bars, SD